{"name":"Dizal Pharmaceuticals","slug":"dizal-pharmaceuticals","ticker":"","exchange":"","domain":"dizal.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AZD4205 and itraconazole","genericName":"AZD4205 and itraconazole","slug":"azd4205-and-itraconazole","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AZD4205 and itraconazole","genericName":"AZD4205 and itraconazole","slug":"azd4205-and-itraconazole","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOQ3ZDRlI1U21ZdGU4aEFqSkF4WDJaaE9rRXRsalpkLVVUZzI1UXB1YWd3YU9VUmYxdklJbV9WeGJwaTZ3ZXlNdXhld015cEVjT2J6RGI3WE55dmtNdWQxcGlOb2lRV0c1YW1XUUlZcG1YNVVqblVXYVRjMC1DU0xWdnlB?oc=5","date":"2026-03-23","type":"pipeline","source":"pharmaphorum","summary":"Dizal breaks new ground for EGFR drugs in lung cancer - pharmaphorum","headline":"Dizal breaks new ground for EGFR drugs in lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOYmRDdWViRzFLVzhXT0lsRWEtN3hqLUdZUzBIaUJBdWprRGhQQS1yZjY1R2FsYXlKNkxISWxWSUg4ZnlUelhYbnNreXhmWEl2TmNVU3hlQWFyYUZpTmwzSW5OTzE0cWdzaF9GWTBjclItVzZqMzByRDlObC1lWDRPc2x2Tkx4aWVuZk45RnlkdFZsMWZodkNjamgxc25fQ3pVUE5B?oc=5","date":"2025-07-14","type":"regulatory","source":"Yicai Global","summary":"China’s Dizal Pharma Gets US Fast-Track Approval for Lung Cancer Drug - Yicai Global","headline":"China’s Dizal Pharma Gets US Fast-Track Approval for Lung Cancer Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNZkdCeFM2eDdpNTNYSWw3VWFwSUpxckJHYThDVVZncHVydWpuYlpvZ0RTZUQtZUZGUFNQc0wwUTZUMFdVM1R3Xy1aQ0E5ellyNjBDMFcxS004OGdNa0FoTnlWZl9NR0RmMk9kbHpmUUxtY2RENEFqMUl2V1QwbkZWSlpmRTdhMXJjNklteklnMmg0b0RubFVDWExjWQ?oc=5","date":"2025-07-10","type":"regulatory","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout - Fierce Pharma","headline":"Fierce Pharma Asia—Approvals for Innovent, Dizal; BMS partner's bispecific ADC readout","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQaHJsSFozaXh1WUtEdU1lbmtSbnp2Z0xlVFRlenVRbjNwLS1NTVR1a21UNmRNYjZ5ZDlVV1BhNHBDeTl5bmV0bWp2MHNlNmpWMldtT1hkcV9nTVF4Skw0LVQ0SEVCVXJCWGNkc2UxUE5TMXowZjIwN1BYY2Y1dFRCVnZtMEpSVkJTbGJFZnNGU3ZEMzlwX2xnRE9ZcVk5QWhOZ1JVeVVR?oc=5","date":"2025-07-07","type":"regulatory","source":"Fierce Pharma","summary":"Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy - Fierce Pharma","headline":"Dizal to challenge J&J with FDA approval for lung cancer drug Zegfrovy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPRDZITmM5Y2o4Qk1IazA2ZnRZb3lKdFdUNWw5Q2pieHU1c0Nkc0s5WFgxSm9BcURpRGlySHA1VWlfbkdhQm1UNjBndklmSFdoT1BiMmpJdzNrMDVrMlppZGhKZ3JCWUQ0YzI3SVhMd29NVFNycDNnd190VTBLZm9UNG1BS3JiVC1EM0d4RHZKeHYzNUdtQUtlX2dRSl8yT3VPbEpF?oc=5","date":"2025-07-03","type":"regulatory","source":"MedCity News","summary":"With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short - MedCity News","headline":"With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBxRzJfWHkzeC1TNkI5Vl80WnBZRmJDZ0hwR0pYdDc0eXo5cnV0ZFFNbk5oWEZHNnlPMlotWHRQNGVkR09LbnBfUHFwdlVJTFdQQ1QwejQxTGxPV0VWbTBmY2VCenUtZzdIYW5QVTZHbENfdEhWcG84NUNmdndpbEU?oc=5","date":"2025-07-03","type":"pipeline","source":"pharmaphorum","summary":"Dizal set to bring lung cancer drug Zegfrovy to US - pharmaphorum","headline":"Dizal set to bring lung cancer drug Zegfrovy to US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFA3S2l1Mk45SGZKZWJIWUprV3pTZjlsRFN0T19IZEZkdEpSdDBySGxYSHhLcUVWMGNXbWZKN0xuUDh6TWxrQUFZZHdYVE9RRDJoa1ZtSVRDcE53ZnRNM2s3dkJvUVlDR3FEWktsYnR1ams4QzBa?oc=5","date":"2025-07-03","type":"trial","source":"Oncology Pipeline","summary":"Dizal's US first; now what? | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Dizal's US first; now what? | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxObmc2MWxVWTJkT1daTkhZM3lLREhQd0NfNHNlWl9KMVVCOGRzOWIzcUNrdm0xX1ViRDdlQ004aWFLNXVVVlhGVHJockVOMml0cmVXam5jYXYzaFAweTlFUHRJcjRFNGNOZURJbEpOVURTVlpQa0l3ZDJ4dDRDS2VxeDQyZ2lLMzByelJYMmdSV2Z1YkFnRl9EeGh3?oc=5","date":"2025-07-03","type":"regulatory","source":"The Pharma Letter","summary":"FDA accelerated approval for Dizal’s sunvozertinib - The Pharma Letter","headline":"FDA accelerated approval for Dizal’s sunvozertinib","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5SM0x6OS00SGlMRE5sakFTemIzbUpkeEljZjVHOVNIcWppRUJqbnlncGdac2N6Y0QxamFvQnZiS1FFc0FselhMbDIwclZ0blBaZlpF?oc=5","date":"2025-07-02","type":"pipeline","source":"FirstWord Pharma","summary":"Dizal's Zegfrovy gets US nod for hard-to-treat lung cancer subset - FirstWord Pharma","headline":"Dizal's Zegfrovy gets US nod for hard-to-treat lung cancer subset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOcmFrbmZpa1E3T0JSRnY0c01GRTN4bVlLeUR6d08zSnFuZzkwSGhiNjh5M0FxX0hLWC1wZTZ1VWdNZU5KNlJrdUpwX2JLb3JXb1lFZTlZVVBhcFZlckgxUlFKLTJKNXJ0UmlFVGhXblB5MHNNc0NlR2F5VXdtVl9NQlJlTVdRZDJFNzNTU3dFTUQ0eDhKUUR4R3NKNnVwUkxBOWM3elB6V2tRa2JvT05wYU55b3FQaUFtSF9FbHgxeFpIcTZzLVBHUUVRbHpiWnV5R2hMY0tQc0F6RlZUOE0xQmFwRVNpa1otY2s3WXBpRGNENlBBRmJRVVllWnZYWGs0RTdTNXJGdTUxWlNuVTNoR212NWVyU2VrbHZzRnVaUDgzLTJVTm1jSXlycEIxemxjSjZEWHh1UnNUU05ZOVpJRlNWbGI?oc=5","date":"2024-11-08","type":"regulatory","source":"PR Newswire","summary":"Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - PR Newswire","headline":"Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell L","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOdi14dW1kQmdzbm9GNGhxMVEwOTFzUjltQ2pfZWlua1RLdFhQWjgtd2RxWEFmX2JoTDNGT01DVjJnS2ZfeUFrZmZteG5oU1cxWk9GakVhV29EMjg0aWNYVkcwRVdxUnhFQVo1WldsR1FyWHIzV19FSldTZGZYaHVJN2x6eUNQXzVGYjlfbEw0OTlpUURMbGNvYmdjbHBPLWVQOEhzbm5paFEzYlFfa1piZ2FCOUZHVUJaQVF5RGYwbUtsN3ZB?oc=5","date":"2023-12-11","type":"regulatory","source":"Fierce Biotech","summary":"ASH: With high tumor response, AstraZeneca spinout Dizal explores FDA path and US partner for PTCL drug - Fierce Biotech","headline":"ASH: With high tumor response, AstraZeneca spinout Dizal explores FDA path and US partner for PTCL drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNXzBqSllUTjZhV3pDSmZEN0gwQVVpbGV2dVdJNHpBeDhBa1g4Z0xsdW9HUUZQTGQ5clRoMnRXekdXQmxnOHJWdWlsek4zT2Jwa2l3dkxyY0NPUDY3encwNUg3LW56MUJfaTBubUFnMlhrakNpNXNVRmg0MmNaT0k1aDYtSlR2cGpFc0s2cEFrR2xMTDAxTTc2bjZtcVp3VmU2YmgyQ2NYYWRlODI0V3p4UWlEOHNITlotcVAwV3dHcWF2dmtlZ1BacTktam44eE1aWTU0ZklVVFMxTnZEM0FZb1BuVlRwZkpvSXJLRS1qRzBQNFM3dWlJQlhNbGsxRnE0dC1vMm1pUm9XbW9qZWlvRng2STNlakk?oc=5","date":"2017-11-27","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China - AstraZeneca","headline":"AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}